General Information of the Molecule (ID: Mol01523)
Name
hsa-mir-551b ,Homo sapiens
Synonyms
microRNA 551b
    Click to Show/Hide
Molecule Type
Precursor miRNA
Gene Name
MIR551B
Gene ID
693136
Location
chr3:168551854-168551949[+]
Sequence
AGAUGUGCUCUCCUGGCCCAUGAAAUCAAGCGUGGGUGAGACCUGGUGCAGAACGGGAAG
GCGACCCAUACUUGGUUUCAGAGGCUGUGAGAAUAA
    Click to Show/Hide
Ensembl ID
ENSG00000207717
HGNC ID
HGNC:32807
Precursor Accession
MI0003575
        Click to Show/Hide the Complete Species Lineage
Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens
Type(s) of Resistant Mechanism of This Molecule
  EADR: Epigenetic Alteration of DNA, RNA or Protein
Drug Resistance Data Categorized by Drug
Approved Drug(s)
1 drug(s) in total
Click to Show/Hide the Full List of Drugs
Cisplatin
Click to Show/Hide
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
       Epigenetic Alteration of DNA, RNA or Protein (EADR) Click to Show/Hide
Disease Class: Ovarian cancer [1]
Sensitive Disease Ovarian cancer [ICD-11: 2C73.0]
Sensitive Drug Cisplatin
Molecule Alteration Expression
Up-regulation
Experimental Note Identified from the Human Clinical Data
In Vitro Model SkOV3 cells Ovary Homo sapiens (Human) CVCL_0532
HEK293T cells Kidney Homo sapiens (Human) CVCL_0063
8910 cells Ovary Homo sapiens (Human) N.A.
In Vivo Model Nude mouse xenograft model Mus musculus
Experiment for
Molecule Alteration
qPCR
Experiment for
Drug Resistance
CCK8 assay; Soft agar colony formation assay
Mechanism Description Down-regulation of Foxo3 and TRIM31 by miR551b in side population promotes cell proliferation, invasion, and drug resistance of ovarian cancer.
References
Ref 1 Downregulation of Foxo3 and TRIM31 by miR-551b in side population promotes cell proliferation, invasion, and drug resistance of ovarian cancer. Med Oncol. 2016 Nov;33(11):126. doi: 10.1007/s12032-016-0842-9. Epub 2016 Oct 14.

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.